Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Allergy and Immunology

The Biology of Mastocytosis: Why Your Cells Are Overacting

At a Glance

Mastocytosis is a rare disorder where the body produces too many overactive mast cells. In over 90% of adults, it is caused by the KIT D816V genetic mutation. While childhood mastocytosis often affects only the skin and resolves by puberty, the adult form is usually chronic and systemic.

Mastocytosis is a rare disorder characterized by the abnormal accumulation and activation of mast cells [1]. Under normal conditions, these cells are vital parts of your immune system, acting as “sentries” that help protect you from pathogens [2]. In mastocytosis, however, these cells are produced in excess and may release chemical signals (mediators) like histamine inappropriately, leading to a wide range of symptoms [3].

Because it is so rare, many patients face a long and frustrating journey to diagnosis. It is common for patients to wait several years—sometimes up to six years—between the first appearance of symptoms and a definitive diagnosis [4][5]. This delay often happens because symptoms like skin rashes or abdominal pain can mimic more common conditions, and many healthcare providers may not have extensive experience with mast cell disorders [6][7].

The Biology: A Light Switch Stuck “On”

In the vast majority of adults with systemic mastocytosis (over 90%), the root cause is a specific genetic change called the KIT D816V mutation [8].

To understand this mutation, imagine a light switch that controls how many mast cells your body makes and how active they are.

  • Normal KIT Receptor: In a healthy body, the “switch” only turns on when it receives a specific signal (called stem cell factor) telling the body it needs more mast cells.
  • KIT D816V Mutation: This mutation changes the shape of the receptor so that it no longer needs a signal to turn on [8]. It becomes constitutively active, meaning the switch is effectively stuck in the “on” position [9].

This “stuck switch” causes mast cells to constantly multiply, survive longer than they should, and release inflammatory chemicals even when there is no real threat [10][11].

Rarity and Prevalence

Mastocytosis is officially classified as a rare disease [12]. While exact global numbers are difficult to pinpoint because many cases go undiagnosed, recent studies suggest the condition may be more common than previously thought due to better testing methods and increased awareness [13][14].

Current research indicates that while it remains rare, increased awareness and more sensitive genetic testing are helping doctors identify systemic forms of the disease that were previously missed [15][16].

Pediatric vs. Adult Mastocytosis

The way mastocytosis behaves depends heavily on whether it begins in childhood or adulthood.

Feature Pediatric Mastocytosis Adult Mastocytosis
Primary Form Usually Cutaneous (limited to the skin) [17]. Usually Systemic (involves internal organs like bone marrow) [17].
Common Signs Reddish-brown skin spots (Urticaria Pigmentosa) [18]. Skin lesions, but often accompanied by organ involvement [19].
Persistence Often improves or resolves spontaneously around puberty [20][21]. Typically persistent and chronic, requiring long-term management [21][22].
Diagnostic Focus Primarily diagnosed through skin examination and the Darier sign (spots hiving up when rubbed) [23]. Often requires a bone marrow biopsy and blood tests for the KIT mutation [24][25].

In children, the disease is often “self-limiting,” meaning it may go away on its own as the child grows [17]. In adults, the condition is usually permanent and requires a care plan focused on managing symptoms and monitoring mast cell levels [2].

For more information on diagnostic subtypes, see The Subtypes & Risk.

Common questions in this guide

What causes adult mastocytosis?
In over 90% of adults with systemic mastocytosis, the root cause is a specific genetic change called the KIT D816V mutation. This mutation causes mast cells to constantly multiply and release inflammatory chemicals even when there is no threat.
What does the KIT D816V mutation do?
The KIT D816V mutation changes a receptor in your cells so that it becomes permanently active. It acts like a light switch stuck in the 'on' position, telling your body to continuously produce and activate mast cells.
Will my child outgrow pediatric mastocytosis?
Pediatric mastocytosis is often self-limiting, meaning it frequently improves or goes away completely on its own around puberty. It is usually confined to the skin rather than affecting internal organs.
Why does it take so long to get a mastocytosis diagnosis?
Diagnosis is often delayed for years because symptoms like skin rashes and abdominal pain can easily mimic more common conditions. Because the disease is rare, many healthcare providers may not immediately suspect a mast cell disorder.
What is the difference between adult and pediatric mastocytosis?
Pediatric mastocytosis primarily affects the skin and often resolves by puberty. Adult mastocytosis is usually systemic, meaning it involves internal organs like the bone marrow, and is typically a chronic condition requiring long-term management.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific type of mastocytosis do I have, and how was it determined?
  2. 2.Did my testing check for the KIT D816V mutation, and if so, what was the 'variant allele frequency' or mutation load?
  3. 3.Is my mastocytosis restricted to my skin, or is there evidence it has reached my bone marrow or other organs?
  4. 4.What is my baseline serum tryptase level, and how often should we monitor it?
  5. 5.Based on my case, what is the likelihood that my symptoms will improve or resolve over time?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Medical algorithm: Peri-operative management of mastocytosis patients.

    Bocca-Tjeertes IFA, van de Ven AAJM, Koppelman GH, et al.

    Allergy 2021; (76(10)):3233-3235 doi:10.1111/all.14891.

    PMID: 33948959
  2. 2

    Pathogenesis and Pathology of Mastocytosis.

    Metcalfe DD, Mekori YA

    Annual review of pathology 2017; (12()):487-514 doi:10.1146/annurev-pathol-052016-100312.

    PMID: 28135563
  3. 3

    Pediatric maculopapular cutaneous mastocytosis: Retrospective review of signs, symptoms, and associated conditions.

    Gurnee EA, Johansen ML, Phung TL, et al.

    Pediatric dermatology 2021; (38(1)):159-163 doi:10.1111/pde.14399.

    PMID: 33068315
  4. 4

    Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case Report.

    Alshurafa A, Abu-Tineh M, Ibrahim FA, et al.

    Case reports in oncology 2023; (16(1)):62-68 doi:10.1159/000529347.

    PMID: 36785740
  5. 5

    Cutaneous mastocytosis: diagnostic challenges and dietary influences.

    Al-Soufi L, Marashli A, HajBakri RC, Al-Shehabi Z

    Dermatology reports 2025; (17(2)) doi:10.4081/dr.2024.10143.

    PMID: 40420700
  6. 6

    Mastocytosis and related entities: a practical roadmap.

    Beyens M, Elst J, van der Poorten ML, et al.

    Acta clinica Belgica 2023; (78(4)):325-335 doi:10.1080/17843286.2022.2137631.

    PMID: 36259506
  7. 7

    Mast Cell Activation Syndrome: A Primer for the Gastroenterologist.

    Weinstock LB, Pace LA, Rezaie A, et al.

    Digestive diseases and sciences 2021; (66(4)):965-982 doi:10.1007/s10620-020-06264-9.

    PMID: 32328892
  8. 8

    Role and significance of c-KIT receptor tyrosine kinase in cancer: A review.

    Sheikh E, Tran T, Vranic S, et al.

    Bosnian journal of basic medical sciences 2022; (22(5)):683-698 doi:10.17305/bjbms.2021.7399.

    PMID: 35490363
  9. 9

    Hereditary alpha-tryptasemia and complete deletion of exon 8 of the c-kit gene in patients with mast cell activation syndrome.

    Jiang M, Vadas P

    Leukemia & lymphoma 2023; (64(7)):1348-1351 doi:10.1080/10428194.2023.2203286.

    PMID: 37086476
  10. 10

    c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation.

    Xiong Y, Taleb M, Misawa K, et al.

    Nature cancer 2023; (4(7)):1001-1015 doi:10.1038/s43018-023-00573-4.

    PMID: 37336986
  11. 11

    Novel KIT mutation, D816_N819delinsll, in a patient with systemic mastocytosis: a case report.

    Juratli HA, Wassmer H, Juskevicius D, et al.

    Virchows Archiv : an international journal of pathology 2025; doi:10.1007/s00428-025-04237-9.

    PMID: 40892237
  12. 12

    Association of systemic mastocytosis with primary cutaneous marginal zone lymphoma; first case.

    Günay MB, Büyükbabani N, Yavuz AS, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(4)):e275-e276 doi:10.1111/jdv.17797.

    PMID: 34753214
  13. 13

    Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study.

    Jørgensen MP, Øvlisen AK, Jensen JF, et al.

    European journal of epidemiology 2025; (40(1)):43-53 doi:10.1007/s10654-024-01195-5.

    PMID: 39751701
  14. 14

    Epidemiology of mastocytosis: a population-based study (Sweden).

    Bergström A, Hägglund H, Berglund A, et al.

    Acta oncologica (Stockholm, Sweden) 2024; (63()):44-50 doi:10.2340/1651-226X.2024.31406.

    PMID: 38380845
  15. 15

    Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey.

    Mesa RA, Sullivan EM, Dubinski D, et al.

    Cancer 2022; (128(20)):3691-3699 doi:10.1002/cncr.34420.

    PMID: 35996873
  16. 16

    Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.

    El Hussein S, Chifotides HT, Khoury JD, et al.

    Cancers 2022; (14(14)) doi:10.3390/cancers14143474.

    PMID: 35884535
  17. 17

    [Cutaneous Manifestations in Mastocytosis: Update].

    Ferreira S, Fernandes I, Cabral R, et al.

    Acta medica portuguesa 2020; (33(4)):275-281 doi:10.20344/amp.12189.

    PMID: 32238242
  18. 18

    Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis.

    Aberer E, Sperr WR, Bretterklieber A, et al.

    The Journal of investigative dermatology 2021; (141(7)):1719-1727 doi:10.1016/j.jid.2020.12.030.

    PMID: 33581142
  19. 19

    Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.

    Gehlen M, Schmidt N, Pfeifer M, et al.

    Calcified tissue international 2021; (109(6)):685-695 doi:10.1007/s00223-021-00887-4.

    PMID: 34223956
  20. 20

    Natural evolution in pediatric cutaneous mastocytosis: 10-year follow-up.

    Czarny J, Renke J, Żawrocki A, et al.

    International journal of dermatology 2021; (60(10)):1253-1257 doi:10.1111/ijd.15542.

    PMID: 33904158
  21. 21

    Current Challenges in the Diagnosis of Pediatric Cutaneous Mastocytosis.

    Ługowska-Umer H, Czarny J, Rydz A, et al.

    Diagnostics (Basel, Switzerland) 2023; (13(23)) doi:10.3390/diagnostics13233583.

    PMID: 38066824
  22. 22

    Systemic mastocytosis associated with Hodgkin's lymphoma in a 4-year-old child.

    Srinivas SM, Agarwal R, Babu N, et al.

    Pediatric dermatology 2020; (37(4)):713-715 doi:10.1111/pde.14183.

    PMID: 32319109
  23. 23

    Cutaneous mastocytosis in childhood.

    Nemat K, Abraham S

    Allergologie select 2022; (6()):1-10 doi:10.5414/ALX02304E.

    PMID: 35028497
  24. 24

    The international consensus classification of eosinophilic disorders and systemic mastocytosis.

    Wang SA, Orazi A, Gotlib J, et al.

    American journal of hematology 2023; (98(8)):1286-1306 doi:10.1002/ajh.26966.

    PMID: 37283522
  25. 25

    Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.

    Jawhar M, Schwaab J, Horny HP, et al.

    European journal of clinical investigation 2016; (46(5)):392-7 doi:10.1111/eci.12607.

    PMID: 26914980

This page explains the biology and underlying genetics of mastocytosis for educational purposes. Always consult your allergist, hematologist, or primary care provider for an accurate diagnosis and personalized treatment plan.

Get notified when new evidence is published on Mastocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.